163 related articles for article (PubMed ID: 11099783)
1. A new in vitro approach for investigating the MPTP effect on DA uptake.
Barc S; Page G; Fauconneau B; Barrier L; Huguet F
Neurochem Int; 2001 Mar; 38(3):243-8. PubMed ID: 11099783
[TBL] [Abstract][Full Text] [Related]
2. Implication of dopamine transporter system on 1-methyl-4-phenylpyridinium and rotenone effect in striatal synaptosomes.
Bougria M; Vitorica J; Cano J; Machado A
Eur J Pharmacol; 1995 Nov; 291(3):407-15. PubMed ID: 8719427
[TBL] [Abstract][Full Text] [Related]
3. Inhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporter.
Clarke PB; Reuben M
Br J Pharmacol; 1995 Jan; 114(2):315-22. PubMed ID: 7881731
[TBL] [Abstract][Full Text] [Related]
4. Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat.
Desole MS; Esposito G; Fresu L; Migheli R; Enrico P; Miele M; De Natale G; Miele E
Neurosci Lett; 1993 Oct; 161(2):121-3. PubMed ID: 7903798
[TBL] [Abstract][Full Text] [Related]
5. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions.
Sirinathsinghji DJ; Heavens RP; McBride CS
Brain Res; 1988 Mar; 443(1-2):101-16. PubMed ID: 3258784
[TBL] [Abstract][Full Text] [Related]
6. Progressive alteration of neuronal dopamine transporter activity in a rat injured by an intranigral injection of MPP+.
Barc S; Page G; Barrier L; Huguet F; Fauconneau B
Brain Res; 2002 Jun; 941(1-2):72-81. PubMed ID: 12031549
[TBL] [Abstract][Full Text] [Related]
7. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium.
Pifl C; Giros B; Caron MG
J Neurosci; 1993 Oct; 13(10):4246-53. PubMed ID: 8410185
[TBL] [Abstract][Full Text] [Related]
8. 1-methyl-4-phenylpyridinium (MPP+) analogs: in vivo neurotoxicity and inhibition of striatal synaptosomal dopamine uptake.
Johnson EA; Wu EY; Rollema H; Booth RG; Trevor AJ; Castagnoli N
Eur J Pharmacol; 1989 Jul; 166(1):65-74. PubMed ID: 2806366
[TBL] [Abstract][Full Text] [Related]
9. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes.
Chiba K; Trevor AJ; Castagnoli N
Biochem Biophys Res Commun; 1985 May; 128(3):1228-32. PubMed ID: 3873939
[TBL] [Abstract][Full Text] [Related]
10. Depletion of striatal dopamine by the N-oxide of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Lau YS; Fung YK; Trobough KL; Cashman JR; Wilson JA
Neurotoxicology; 1991; 12(2):189-99. PubMed ID: 1956580
[TBL] [Abstract][Full Text] [Related]
11. Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice.
Moy LY; Albers DS; Sonsalla PK
Brain Res; 1998 Apr; 790(1-2):264-9. PubMed ID: 9593931
[TBL] [Abstract][Full Text] [Related]
12. Acetaldehyde directly enhances MPP+ neurotoxicity and delays its elimination from the striatum.
Zuddas A; Corsini GU; Schinelli S; Barker JL; Kopin IJ; di Porzio U
Brain Res; 1989 Oct; 501(1):11-22. PubMed ID: 2804689
[TBL] [Abstract][Full Text] [Related]
13. MPTP toxicity in rat striatal slices: dopamine uptake alteration does not appear to be related to lipid peroxidation.
Huguet F; Page G; Morel P; Tallineau C; Piriou A
Toxicology; 1997 Sep; 122(1-2):93-9. PubMed ID: 9274805
[TBL] [Abstract][Full Text] [Related]
14. Serotonergic conversion of MPTP and dopaminergic accumulation of MPP+.
Shen RS; Abell CW; Gessner W; Brossi A
FEBS Lett; 1985 Sep; 189(2):225-30. PubMed ID: 3876242
[TBL] [Abstract][Full Text] [Related]
15. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter.
Gainetdinov RR; Fumagalli F; Jones SR; Caron MG
J Neurochem; 1997 Sep; 69(3):1322-5. PubMed ID: 9282960
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
McNaught KS; Thull U; Carrupt PA; Altomare C; Cellamare S; Carotti A; Testa B; Jenner P; Marsden CD
Biochem Pharmacol; 1996 Jul; 52(1):29-34. PubMed ID: 8678905
[TBL] [Abstract][Full Text] [Related]
17. Toxic effects of MPP(+) and MPTP in PC12 cells independent of reactive oxygen species formation.
Fonck C; Baudry M
Brain Res; 2001 Jun; 905(1-2):199-206. PubMed ID: 11423095
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of [3H]MPP+ uptake in dopaminergic neurons of mouse: regional effects of MPTP neurotoxicity.
Sershen H; Mason MF; Debler EA; Lajtha A
Eur J Pharmacol; 1986 Jul; 126(3):337-9. PubMed ID: 3489627
[TBL] [Abstract][Full Text] [Related]
19. MPP+-induced increases in extracellular potassium ion activity in rat striatal slices suggest that consequences of MPP+ neurotoxicity are spread beyond dopaminergic terminals.
Hollinden GE; Sanchez-Ramos JR; Sick TJ; Rosenthal M
Brain Res; 1988 Dec; 475(2):283-90. PubMed ID: 3265070
[TBL] [Abstract][Full Text] [Related]
20. Prolonged alterations in canine striatal dopamine metabolism following subtoxic doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 4'-amino-MPTP are linked to the persistence of pyridinium metabolites.
Johannessen JN; Sobotka TJ; Weise VK; Markey SP
J Neurochem; 1991 Sep; 57(3):981-90. PubMed ID: 1677682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
